Trastuzumab-induced thrombocytopenia after eight cycles of trastuzumab treatment
Trastuzumab, a humanized monoclonal antibody derived from recombinant DNA, is used in patients with breast cancer with HER2 gene amplification. The survival benefit from trastuzumab has been well established in patients with early and metastatic breast cancer who had over expression of HER2. We repo...
Main Authors: | Zhou Qiong, Dong Jie, Jiang Xiaodong, Pan Yueyin, Han Xinghua |
---|---|
Format: | Article |
Language: | English |
Published: |
De Gruyter
2020-07-01
|
Series: | Open Medicine |
Subjects: | |
Online Access: | https://doi.org/10.1515/med-2020-0201 |
Similar Items
-
Trastuzumab Cures Cancer and Disrupts the Practice of Cardiology∗
by: Richard M. Steingart, MD, et al.
Published: (2019-09-01) -
Lapatinib in combination with capecitabine versus continued use of trastuzumab in breast cancer patients with trastuzumab-resistance: a retrospective study of a Chinese population
by: Fan Yang, et al.
Published: (2020-03-01) -
Safety of Continuing Trastuzumab Despite Mild Cardiotoxicity
by: Darryl P. Leong, MBBS, MPH, MBiostat, PhD, et al.
Published: (2019-09-01) -
Trastuzumab-Induced Myocardiotoxicity Mimicking Acute Coronary Syndrome
by: K.B. Ribeiro, et al.
Published: (2012-03-01) -
Effectiveness of adjuvant trastuzumab in daily clinical practice
by: Matos Erika, et al.
Published: (2014-12-01)